Cost-effectiveness analysis of transarterial chemoembolization combined with lenvatinib as the first-line treatment for advanced hepatocellular carcinoma
Purpose: Results from the LAUNCH trial suggest transarterial chemoembolization (TACE) in combination with lenvatinib is significantly more effective than lenvatinib as a first-line treatment option for advanced hepatocellular carcinoma (HCC). However, the cost of TACE is substantial. This study comp...
| Главные авторы: | , , , , , , |
|---|---|
| Формат: | Статья |
| Язык: | English |
| Опубликовано: |
Frontiers Media S.A.
2023-09-01
|
| Серии: | Frontiers in Pharmacology |
| Предметы: | |
| Online-ссылка: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1219694/full |